|| Checking for direct PDF access through Ovid
68Ga-PSMA PET/CT is the upcoming imaging modality for staging, restaging and response assessment of prostate cancer. However, due to neuroendocrine differentiation in some of patients with prostate cancer, they express somatostatin receptors instead of prostate specific membrane antigen. This can be exploited and other modalities like 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT should be used in such cases for guiding management. We hereby discuss a similar case of 67-year-old man of adenocarcinoma prostate with neuroendocrine differentiation, which shows the potential pitfall of 68Ga-PSMA PET/CT imaging and benefit of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in such cases.